Restoration of bax in prostate cancer suppresses tumor growth and augments therapeutic cell death induction

Anticancer Research

Volumn 21, Issue 5, 2001, Pages 3141-3146

  Honda, Tsuyoshi ^a   Gjertsen, Bjorn T ^a   Spurgers, Kevin B ^a   Briones, Fermin ^a   Lee, Sang Jun ^a   Hobbs, Marvette L ^a   Meyn, Raymond E ^a   Roth, Jack A ^a   Logothetis, Christopher ^a   McDonnell, Timothy J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Apoptosis; Bax; Chemotherapy; Prostate cancer; Radiation therapy; Tumor suppressor

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; PACLITAXEL; PROTEIN BAX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL DESTRUCTION; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA TRANSFECTION; GAMMA IRRADIATION; HUMAN; HUMAN CELL; LD 50; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BCL-2-ASSOCIATED X PROTEIN; CELL DEATH; CELL DIVISION; HEMAGGLUTININS; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RADIATION TOLERANCE; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0035572790     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. New agents in the therapy of hormone-refractory patients with prostate cancer
2. Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer
3. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers
4. Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma
5. p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy
6. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death
7. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
8. Bax suppresses tumorigenesis and stimulates apoptosis in vivo
9. Molecular correlates of bcl-2 enhanced growth following androgen-ablation in prostate carcinoma cells in vivo
10. The impact of bcl-2 expression and bax deficiency on prostate homeostasis in vivo
11. p53 oncogene mutations in three human prostate cancer cell lines
12. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutater phenotype
13. An improved MTT assay
14. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation
15. Implications of apoptotic cell death regulation in cancer therapy
16. Bcl-2/Bax: A rheostat that regulates an anti-oxidant pathway and cell death
17. Role of MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines
18. Overexpression of bax gene sensitizes K562 erythroleukemia cells to apoptosis induced by selective chemotherapeutic agents
19. Bax enhances paclitaxel-induced apoptosis through a p53-independent pathway
20. Bax overexpression enchances cytochrom c release from mitochondria and sensitizes KATOIII gastric cancer cells to chemotherapeutic agent-induced apoptosis
21. Overexpression of bax sensitizes breast cancer MCF-7 cells to cisplatin and etoposide
22. Bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53- dependent apoptosis
23. Reduced expression of proapoptotic gene bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma
24. A multivariate analysis of tumour biological factors predicting response to cytotoxic treatment in advanced breast cancer
25. Bax- deficient mice with lymphoid hyperplasia and male germ cell death
26. Up-regulation of the proapoptotic mediators bax and bak following adenovirus-mediated p53 gene transfer in lung cancer cells
27. Over-expression of bax sensitizes breast cancer MCF-7 cells to radiation-induced apoptosis
28. Bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer
29. Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice
30. TabBO: A model reflecting common molecular features of androgen-independent prostate cancer
31. An elevated bax/bcl-2 ratio corresponds with the onset of prostate epithelial cell apoptosis
32. Bcl-2 confers androgen independence in androgen sensitive prostatic carcinoma